GCG and obesity disorder: In addition, in a subanalysis from the study of Tirzepatide in Participants with Heart Failure with Preserved Ejection fraction and Obesity (SUMMIT) trial, the dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 agonist tirzepatide mainly reduced extrapericardial adipose tissue, the adipose tissue situated outside the parietal pericardium, which is less likely to cause pericardial constraint, and not EAT itself.33